Clinical Trials Logo
  1. Home
  2. Liver Fibrosis
  3. NCT05115942

Hydronidone for the Treatment of Liver Fibrosis Associated With Chronic Viral Hepatitis B Phase 3 Trial.

Liver Fibrosis Clinical Trial

Official title:
Hydronidone for the Treatment of Liver Fibrosis Associated With Chronic Hepatitis B:Randomized,Double-blind,Placebo-controlled,Entecavir Basic Treatment,Multicentre Phase 3 Trial.

Clinical Trial Summary

This study was a randomized, double-blind, placebo-controlled, entecavir basic treatment, multicentre clinical study. The main objective of this study was to confirm the efficacy and safety of hydronidone in the treatment of chronic hepatitis B liver fibrosis.

Clinical Trial Description

248 patients with chronic viral hepatitis B liver fibrosis were enrolled in this 52-week study, and randomized into hydronidone or placebo group. Each group has 124 subjects. Both groups were treated with entecavir antiviral basic therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05115942
Study type Interventional
Source Beijing Continent Pharmaceutical Co, Ltd.
Contact Ling Zhang, Dr.
Phone +86-13501209210
Email zhangling@bjcontinent.com
Status Recruiting
Phase Phase 3
Start date December 30, 2021
Completion date June 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Recruiting NCT06051669 - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Recruiting NCT06098417 - Biomarkers in the Diagnosis and Prognosis of NAFLD
Not yet recruiting NCT03623360 - Functional MRI to Determine Severity of Cirrhosis
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Not yet recruiting NCT01133184 - Improved Prevention of Perinatal Hepatitis B Transmission Phase 4
Completed NCT00043303 - Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis Phase 2
Completed NCT03872024 - Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients N/A
Recruiting NCT05912179 - Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
Recruiting NCT04533828 - 68Ga-FAPI PET/CT in Liver Fibrosis Patients Early Phase 1
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Recruiting NCT03277651 - Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension N/A
Completed NCT01707472 - Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis Phase 2
Not yet recruiting NCT05935488 - Early Liver Disease Breath Detection
Completed NCT01810458 - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Completed NCT02060162 - Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed NCT00049842 - Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) Phase 3